Navigation Links
JDRF and Amylin Partner to Investigate Co-Formulating Two Hormones for Treatment of Type 1 Diabetes
Date:5/10/2011

omes a daily balancing act," said Matthew Riddle, M.D., Professor of Medicine, Division of Endocrinology, Diabetes, & Clinical Nutrition, Oregon Health & Science University. "Pramlintide may provide additional benefit for these patients by stabilizing their blood sugar levels, so they spend more time in the normal glucose range."

Currently, patients who use pramlintide must separately administer their daily insulin therapy, either through injections or an insulin pump. A co-formulated therapy that harnesses the benefit of both hormones might better mimic the natural physiology of the pancreas and simplify dosing decisions.

"Ultimately, it might reduce the complexity of daily treatment for patients who are working hard to manage this disease, and improve their ability to achieve treatment goals," continued Dr. Riddle.

About the Research Collaboration

This is the second research collaboration between JDRF and Amylin to advance innovative treatments for people with type 1 diabetes. This collaboration, consisting of formulation and clinical work, will investigate whether a fixed ratio of pramlintide and insulin can effectively help treat type 1 diabetes. The formulation research will assess the feasibility of co-formulating pramlintide and insulin (both currently administered using separate injections) as a single injection. An optimal ratio of pramlintide and insulin will be identified through modeling work.  In a series of up to three clinical proof-of-concept studies, the program will also investigate the optimal pramlintide:insulin dose ratios, and determine whether delivering pramlintide and insulin in this fixed ratio, can improve glucose control and optimize treatment of type 1 diabetes compared with insulin alone.

The collaboration between JDRF and Amylin is part of JDRF's Industry Discovery and Development Partnership (IDDP) program to accelerate research that will lead to better treatments and a cure for
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.; Juvenile Diabetes Research Foundation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Amylin Pharmaceuticals to Present at the Bank of America 2011 Healthcare Conference
2. Amylin Pharmaceuticals to Present at the Deutsche Bank 36th Annual Healthcare Conference
3. Amylin Pharmaceuticals Reports First Quarter Financial Results
4. Amylin to Present Data Showing Investigational Metreleptin Treatment Led to Long-Term Improvements in Diabetes and Lipid Control in Patients with Lipodystrophy
5. Amylin and Takeda Voluntarily Suspend Clinical Activities in Obesity Trial
6. Amylin Pharmaceuticals to Present at the Barclays Capital 2011 Global Healthcare Conference
7. Amylin Pharmaceuticals to Present at the 2011 ISI Annual Conference
8. Amylin Pharmaceuticals Reports 2010 Financial Results
9. Amylin Pharmaceuticals to Webcast Year-End Financial Results
10. Amylin Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
11. Amylin Submits Clinical and Nonclinical Sections of Rolling Biologics License Application for Metreleptin to Treat Rare Forms of Lipodystrophy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 BreedIT Corp (OTC: BRDT), ... distributor of highly sophisticated agro-breeding solutions for plant breeders ... the Company,s board of directors appointed chemistry and pharmaceutical ... new member of the board. From 1975 ... Pharmaceutical Industries Ltd (NYSE: TEVA ) and ...
(Date:1/15/2014)... -- Tegra Medical is very pleased to announce the ... its new Chief Executive Officer.  Mark was promoted from ... he has overseen the company,s four facilities in ... and Costa Rica.  Mr. King joined Tegra Medical in ... and manufacturing experience in medical device businesses, both in ...
(Date:1/15/2014)... 2014 The Cadence Fitness & Health ... Center by the Medical Fitness Association, a non-profit ... to achieve their full potential. The Cadence Fitness ... center in the western suburbs and second in ... the Cadence Fitness & Health Center meets guidelines ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
... Cochlear, the global leader in implantable hearing ... Clark Cochlear Scholarship. Presented by Cochlear Americas, the Graeme ... seniors who,ve demonstrated exceptional achievements both in the classroom ... implant and will receive financial assistance toward their chosen ...
... PHILADELPHIA , May 4 ... SHPGY ), the global specialty biopharmaceutical company, today announced ... a change to the prescribing information for its once-daily ... ® (lisdexamfetamine dimesylate) Capsules CII, to include supplemental ...
Cached Medicine Technology:Cochlear Americas Honors Achievements of Cochlear Implant Recipients during May's Better Hearing & Speech Month 2Cochlear Americas Honors Achievements of Cochlear Implant Recipients during May's Better Hearing & Speech Month 3Cochlear Americas Honors Achievements of Cochlear Implant Recipients during May's Better Hearing & Speech Month 4FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD 2FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD 3FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD 4FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD 5FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD 6FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD 7FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD 8
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... Feb. 27 Novartis and Sony Pictures Television,International,s ... a breast cancer prevention and early detection campaign ... combines,Novartis, resources and expertise in oncology and SPTI,s ... their fight against breast cancer.,The campaign is called ...
... Feb. 27 Today, the U.S. House,Foreign Affairs ... the U.S. Global Leadership Against HIV/AIDS, Tuberculosis, and,Malaria ... Family Research Council, released the,following statement:, "I ... an HIV/AIDS,bill free of troubling provisions contained in ...
... The UCLA Department of Family Medicine, with support from the ... Research on Health and Healthcare, a group that will study ... , The network will also mentor and develop a ... disparities. , The new group to ...
... can show injury in as little as 6 days ... sclerosis drug Tysabri can start causing liver damage within six ... , In January, the U.S. Food and Drug Administration expanded ... inflammation of the digestive tract. , The drug has also ...
... Wellesse announces the launch,of its first-ever online sweepstakes, ... enter for a chance to win a year,s ... at, http://www.wellesse.com . The sweepstakes launched February 14, ... newest online campaign is part of our overall ...
... Acura,Pharmaceuticals, Inc. (Nasdaq: ACUR ) announced that ... leave of absence for health,reasons for an as-yet undetermined ... of the Company,s Board of Directors. At the same ... to serve as,non-executive Chairman of the Board. Mr. Markham ...
Cached Medicine News:Health News:Novartis and Sony Pictures Television International's Latin American Advertising Sales Group Launch Partnership to Create Multi-Media Platform for Breast Cancer Awareness, Detection, and Treatment in Latin America 2Health News:Novartis and Sony Pictures Television International's Latin American Advertising Sales Group Launch Partnership to Create Multi-Media Platform for Breast Cancer Awareness, Detection, and Treatment in Latin America 3Health News:Novartis and Sony Pictures Television International's Latin American Advertising Sales Group Launch Partnership to Create Multi-Media Platform for Breast Cancer Awareness, Detection, and Treatment in Latin America 4Health News:UCLA launches network to study health care disparities affecting minorities 2Health News:Tysabri May Cause Liver Damage, Health Officials Say 2Health News:WELLESSE(TM) Announces the 'Keep Your Body in Motion' Sweepstakes 2Health News:Acura Pharmaceuticals, Inc. Announces Andrew Reddick, President & CEO, To Take Medical Leave and Appointment of Richard Markham as Chairman of the Board 2Health News:Acura Pharmaceuticals, Inc. Announces Andrew Reddick, President & CEO, To Take Medical Leave and Appointment of Richard Markham as Chairman of the Board 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: